Reversal of multidrug-resistance in human leukemia cell line K562/A02 by tyrosine kinase inhibitors / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 90-95, 2010.
Article
de Zh
| WPRIM
| ID: wpr-328566
Bibliothèque responsable:
WPRO
ABSTRACT
This study was aimed to investigate the reversal effect of tyrosine kinase inhibitors (TKI) Imatinib and Nilotinib on multidrug-resistant cell line K562/A02. The expression levels of mdr-1 mRNA and bcr-abl mRNA were assayed by RT-PCR. The protein levels of P-glycoprotein (P-gp) and P210 were detected by Western blot. The daunorubicin (DNR) accumulation in K562/A02 cells were analyzed by flow cytometry (FCM). The results showed that the 0.0625 micromol/L Imatinib or 5 nmol/L Nilotinib alone had no cytotoxic effect on the inhibition of K562/A02 cells. When K562/A02 cells were treated with Imatinib or Nilotinib alone for 48 hours, the expressions of mdr-1 mRNA, der/abl mRNA, P-gp and P210 protein were all down-regulated, furthermore the effect of Nilotinib was stronger than that of Imatinib. The detection of fluorescence intensity revealed that the DNR concentration in K562/A02 cells treated with Imatinib or Nilotinib alone for 48 hours were 7.85% and 12.02% of K562 cells respectively. It is concluded that the tyrosine kinase inhibitors show great effect reversing drug resistance of cells, moreover, the effect of Nilotinib is stronger than that of Imatinib.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Pharmacologie
/
Pipérazines
/
Pyrimidines
/
Benzamides
/
Daunorubicine
/
Doxorubicine
/
Glycoprotéine P
/
Multirésistance aux médicaments
/
Résistance aux médicaments antinéoplasiques
/
Sous-famille B de transporteurs à cassette liant l'ATP
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Journal of Experimental Hematology
Année:
2010
Type:
Article